Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
|ClinicalTrials.gov Identifier: NCT01198808|
Recruitment Status : Unknown
Verified January 2012 by Technische Universität München.
Recruitment status was: Active, not recruiting
First Posted : September 10, 2010
Last Update Posted : January 18, 2012
Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and regulatory T cells. The found data will be correlated to clinical data such as the cancer-specific survival and the response to chemotherapy.
It is hypothesized that those patients with a high number of Tregs and no tumor-specific T-cells have a worse prognosis.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters|
|Study Start Date :||August 2010|
|Primary Completion Date :||December 2011|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01198808
|Urologische Klinik der Technischen Universität München|
|Munich, Bavaria, Germany, 81675|
|Principal Investigator:||Thomas Horn, MD||Department of Urology, Technische Universität München|